PD08-02 MICROWAVE ABLATION OF RENAL CELL CARCINOMA: ONCOLOGIC AND FUNCTIONAL OUTCOMES AT A SINGLE CENTER

Abstract

You have accessJournal of UrologyKidney Cancer: Localized: Ablative Therapy (PD08)1 Apr 2020PD08-02 MICROWAVE ABLATION OF RENAL CELL CARCINOMA: ONCOLOGIC AND FUNCTIONAL OUTCOMES AT A SINGLE CENTER Rand Wilcox Vanden Berg*, Lina Posada Calderon, Samuel LaRussa, Kiersten Craig, and Timothy McClure Rand Wilcox Vanden Berg*Rand Wilcox Vanden Berg* More articles by this author , Lina Posada CalderonLina Posada Calderon More articles by this author , Samuel LaRussaSamuel LaRussa More articles by this author , Kiersten CraigKiersten Craig More articles by this author , and Timothy McClureTimothy McClure More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000835.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Percutaneous ablation is an established alternative to surgical intervention for small renal tumors. Radiofrequency and cryoablation have been studied extensively in the literature. To date, series assessing the efficacy and safety of microwave ablation (MWA) are limited. We present a single-center cohort of 102 patients treated with MWA for renal tumors. METHODS: After obtaining institutional review board approval, a review of the medical record between September 2016 and August 2019 was performed, identifying 102 patients (110 tumors), who were enrolled retrospectively. All ablations were performed by a single board-certified urologist/interventional radiologist. Demographic information, intraoperative, postoperative, and follow-up surveillance data was recorded. RESULTS: Mean age was 67.8 years (SD 10.3) of which 30.4% were female. Average BMI was 28.0 (SD 5.0) with an average Charleston Comorbidity Index of 5.2 (SD 1.8). 29 tumors were biopsy confirmed as papillary carcinoma, 40 as clear cell renal cell carcinoma, 14 as oncocytic neoplasm, 3 as chromophobe, 17 as benign, and in 7 cases pathology was unavailable for review. Average tumor size was 2.1 cm (SD 1.3). Average RENAL score was 6.4 (SD 1.7). Technical success was achieved in all patients, and all but one patient were discharged on the same day. Median eGFR at baseline and 1 year was 75.9 (IQR 58.9-87.3) and 65.1 (IQR 58.8-79.8), respectively (difference 10.8, p=0.32). 2 Clavien-Dindo type I complications (nausea and vomiting), 1 type II complication (bradycardia requiring atropine), and one type III complication (bleeding requiring embolization) were experienced in this cohort. Post-procedure surveillance was performed with either CT or MRI. Average follow-up was 261 days (IQR 65-400, range 0-1323) with 2 tumors having recurred to date. CONCLUSIONS: Microwave ablation is a safe and efficacious treatment option for small renal masses with minimal adverse events and low rates of recurrence in this cohort of 102 patients. Continued follow-up is needed to assess long-term outcomes. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e167-e168 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rand Wilcox Vanden Berg* More articles by this author Lina Posada Calderon More articles by this author Samuel LaRussa More articles by this author Kiersten Craig More articles by this author Timothy McClure More articles by this author Expand All Advertisement PDF downloadLoading ...